Financial Performance Overview
Tejnaksh Healthcare Limited reported weak financial results for FY 2025-26, with standalone revenue declining 18.4% to ₹717.72 lakhs and profit after tax dropping 47.4% to ₹137.98 lakhs. On a consolidated basis, revenue decreased to ₹1,078.69 lakhs from ₹1,289.71 lakhs in FY25, while net profit declined to ₹123.76 lakhs from ₹234.45 lakhs. Basic EPS stood at ₹0.68 (standalone) and ₹0.61 (consolidated).
Subsidiary Performance and Capital Structure
The subsidiary Tej Vedaant Healthcare Private Limited reported revenue of ₹438.43 lakhs with a net loss of ₹18.88 lakhs. The company increased its authorized share capital to ₹1,050.00 lakhs while maintaining issued capital at ₹1,015.68 lakhs. No bonus shares, buybacks, or dividend distributions occurred during the year.
Annual General Meeting and Corporate Governance
The 19th AGM is scheduled for September 29, 2026, to seek shareholder approval for director reappointments, including Mr. Sanjay Bhikajirao Khatal and Mr. Suhas Vasantrao Thorat as Independent Director. The meeting will also approve material related party transactions with a maximum value of ₹100 lakhs annually involving Tej Vedaant Healthcare, Dr. Ashish Rawandale, and Tejnaksh Healthcare Foundation.
Asset Position and Key Ratios
Significant additions were made to intangible assets under development (₹36.00 lakhs) and right-of-use assets (₹36.40 lakhs). Key ratios showed deterioration with return on equity declining to 4-5.29% from 9-10.88% in FY25, and net profit margin falling to 10.95-19.22% from 17.29-29.81%. The current ratio improved to 8.45-11.22 times.
Regulatory Compliance and Audit
The company maintained compliance with SEBI LODR regulations, with unqualified audit opinions from both statutory and secretarial auditors. No CSR expenditure was incurred, and no material regulatory actions or compliance issues were reported during the period.